Novel approaches to the therapy of steroid-resistant acute graft-versus-host disease

Joseph H. Antin, Allen R. Chen, Daniel R. Couriel, Vincent T. Ho, Richard A. Nash, Daniel Weisdorf

Research output: Contribution to journalReview articlepeer-review

65 Scopus citations


Despite initial encouraging results, preliminary results showed no significant differences in response between the MP and MP plus infliximab groups. In the M.D. Anderson phase III experience, the incidence of infection and causative organisms were similar in both groups, although an increased risk of fungalinfections has been recently reported, and cautious use of this agent should probably include antifungalprophyl axis [100]. Despite encouraging response rates in the steroid-refractory setting, treatment of acute GVHD at an earlier stage with infliximab did not prove more effective than steroids alone. Once established, GVHD continues to be the main cause of death.

Original languageEnglish (US)
Pages (from-to)655-668
Number of pages14
JournalBiology of Blood and Marrow Transplantation
Issue number10
StatePublished - Oct 2004

Bibliographical note

Funding Information:
This work was supported by grant nos. HL070149, CA18029, and HL36444 from the National Institutes of Health (Bethesda, MD).


Dive into the research topics of 'Novel approaches to the therapy of steroid-resistant acute graft-versus-host disease'. Together they form a unique fingerprint.

Cite this